ATGL acts as a control mechanism of lipolysis, as variations in diacylglycerol concentration impact enzymes in later stages of lipolysis.[11]
Clinical significance
Defects in ATGL can cause problems in lipolysis, leading to
neutral lipid storage disease.[12] As triacylglycerols are not hydrolysed to diacylglycerols, there is a build-up of triacylglycerol droplets in
granulocytes.[12]
ATGL is regulated by insulin, and is similar to structure with adiponutrin, a protein that is regulated by nutrition. When there is a lack of insulin, there is an increased expression of the ATGL protein. Because adipose tissue triglyceride is a major form of energy storage, the study of how ATGL regulation and dysregulation can lead to potential problems will increase understanding of the pathophysiology behind metabolic disorders.[13] ATGL is also the key enzyme that would be able to maintain a balance between mobilization and lipid storage. Lipolytic breakdown performed by ATGL would impact regulatory functions including but not limited to cell death, growth, signaling, metabolism, and gene expression.[14][15]
Regulation
There must be mechanisms set to maintain the balance between energy storage, and energy release; a dysregulation in the equilibrium result in metabolic disorder, a prime one being diabetes.[13] Adipose Triglyceride Lipase (ATGL) can undergo activation through two different pathways: transcriptionally and through post-translational modification. Through the transcriptional pathway, Beta-adrenergic, a receptor that can form a complex with agonist such as epinephrine, results in the signal transduction pathway activation of Adipose Triglyceride Lipase (ATGL). The alternative pathway is through a post-translational modification specifically phosphorylation of a serine 406 residue located on the enzyme by a kinase known as AMP activated protein kinase (AMPK). Both pathways facilitate the activation of the enzyme, resulting in the breakdown of triglyceride.[16]
Insulin is a hormone that regulate the enzyme ATGL, it inhibits the enzyme by favoring lipid storage over lipolysis.[13] One pathway of inhibition of ATGL when insulin is present is the activation of SIRT1, which inhibits FoxO1.[16][17] Specifically, FoxO1 is repressed from localizing in the nucleus by deacetylation in adipocytes.[16][18]
^
abOjha S, Budge H, Symonds ME (2014). "Adipocytes in Normal Tissue Biology". In McManus LM, Mitchell RN (eds.). Pathobiology of Human Disease. San Diego: Academic Press. pp. 2003–2013.
doi:
10.1016/b978-0-12-386456-7.04408-7.
ISBN978-0-12-386457-4.
^
abcLehner R, Quiroga AD (2016). "Chapter 5 - Fatty Acid Handling in Mammalian Cells". In Ridgway ND, McLeod RS (eds.). Biochemistry of Lipids, Lipoproteins and Membranes (Sixth ed.). Boston: Elsevier. pp. 149–184.
doi:
10.1016/b978-0-444-63438-2.00005-5.
ISBN978-0-444-63438-2.
^Tsiloulis T, Watt MJ (2015). "Chapter Eight - Exercise and the Regulation of Adipose Tissue Metabolism". In Bouchard C (ed.). Progress in Molecular Biology and Translational Science. Molecular and Cellular Regulation of Adaptation to Exercise. Vol. 135. Academic Press. pp. 175–201.
doi:
10.1016/bs.pmbts.2015.06.016.
ISBN9780128039915.
PMID26477915.
^Zhang X, Heckmann BL, Liu J (2013-01-01). "Studying lipolysis in adipocytes by combining siRNA knockdown and adenovirus-mediated overexpression approaches". In Yang P, Li H (eds.). Lipid Droplets. Methods in Cell Biology. Vol. 116. Academic Press. pp. 83–105.
doi:
10.1016/b978-0-12-408051-5.00006-1.
ISBN9780124080515.
PMC4529287.
PMID24099289.
^
abBongarzone ER, Givogri MI, Darryl C, DiMauro S (January 2012). "Inborn Metabolic Defects of Lysosomes, Peroxisomes, Carbohydrates, Fatty Acids and Mitochondria.". In Brady ST, Siegel GJ, Albers RW, Price DL (eds.). Basic Neurochemistry (Eighth ed.). New York: Academic Press. pp. 755–782.
doi:
10.1016/b978-0-12-374947-5.00043-2.
ISBN978-0-12-374947-5.
Fischer J, Lefèvre C, Morava E, Mussini JM, Laforêt P, Negre-Salvayre A, et al. (January 2007). "The gene encoding adipose triglyceride lipase (PNPLA2) is mutated in neutral lipid storage disease with myopathy". Nature Genetics. 39 (1): 28–30.
doi:
10.1038/ng1951.
PMID17187067.
S2CID23679419.
Rydén M, Jocken J, van Harmelen V, Dicker A, Hoffstedt J, Wirén M, et al. (June 2007). "Comparative studies of the role of hormone-sensitive lipase and adipose triglyceride lipase in human fat cell lipolysis". American Journal of Physiology. Endocrinology and Metabolism. 292 (6): E1847–E1855.
CiteSeerX10.1.1.328.3523.
doi:
10.1152/ajpendo.00040.2007.
PMID17327373.
Steinberg GR, Kemp BE, Watt MJ (October 2007). "Adipocyte triglyceride lipase expression in human obesity". American Journal of Physiology. Endocrinology and Metabolism. 293 (4): E958–E964.
doi:
10.1152/ajpendo.00235.2007.
PMID17609260.